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ABSTRACT
This study compared patients with moderate-to-severe community-acquired pneumonia (CAP)
requiring hospitalisation, who received initial therapy with either intravenous ceftriaxone plus
intravenous azithromycin, followed by step-down to oral azithromycin (n = 135), with patients who
received intravenous ceftriaxone combined with either intravenous clarithromycin or erythromycin,
followed by step-down to either oral clarithromycin or erythromycin (n = 143). Clinical and
bacteriological outcomes were evaluated at the end of therapy (EOT; day 12–16) or at the end of
study (EOS; day 28–35). At baseline, mean APACHE II scores were 13.3 and 12.6, respectively, with
>50% of patients classiﬁed as Fine Pneumonia Severity Index (PSI) category IV or V. Clinical success
rates (cure or improvement) in the modiﬁed intent-to-treat (MITT) population at EOT were 84.3% in the
ceftriaxone/azithromycin group and 82.7% in the ceftriaxone/clarithromycin or erythromycin group.
At EOS, MITT success rates (cure only) were 81.7% and 75.0%, respectively. Equivalent success rates in
the clinically evaluable population were 83% and 87%, respectively, at EOT, and 79% and 78%,
respectively, at EOS. MITT bacteriological eradication rates were 73.2% and 67.4%, respectively, at EOT,
and 68.3% vs. 60.9%, respectively, at EOS. Mean length of hospital stay (LOS) was 10.7 and 12.6 days,
and the mean duration of therapy was 9.5 and 10.5 days, respectively. The incidence of infusion-related
adverse events was 16.3% and 25.2% (p 0.04), respectively. An intravenous-to-oral regimen of
ceftriaxone/azithromycin was at least equivalent in efﬁcacy and safety to the comparator regimen and
appeared to be a suitable treatment option for hospitalised patients with CAP.
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INTRODUCTION
Community-acquired pneumonia (CAP) remains
a signiﬁcant cause of morbidity and mortality
worldwide. Effective medical intervention
requires that initial antimicrobial therapy is active
against the causative organism(s), but identiﬁca-
tion of the pathogen remains undetermined at the
time therapy is initiated in most cases. Bacterio-
logical culture results are positive in <50% of
hospitalised patients, even in the idealised setting
of prospective studies [1]. In data from 26 pros-
pective studies conducted in ten western Euro-
pean countries, the most common causative
pathogen in 5961 patients hospitalised with CAP
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was Streptococcus pneumoniae, followed by the
atypical pathogens Chlamydophila (Chlamydia)
pneumoniae, Mycoplasma pneumoniae and Legionella
spp. [2]. Accordingly, empirical therapy for CAP
is usually directed against these pathogens [3,4].
As atypical pathogens, e.g., C. pneumoniae, M.
pneumoniae and Legionella spp., have been found
to be common in patients with CAP in some
studies, many investigators recommend that
empirical antibiotic treatment should cover these
organisms [5].
Several treatment guidelines, including those of
the European Respiratory Society (ERS) Task
Force [6], the American Thoracic Society (ATS)
[7] and the Infectious Diseases Society of America
(IDSA) [8], include a b-lactam/macrolide combi-
nation for the treatment of hospitalised patients
with CAP. For management of a patient in the
general medical ward, current ERS guidelines
recommend ﬁrst-line therapy with a second- or
third-generation cephalosporin, b-lactam/b-lacta-
mase inhibitor, benzyl penicillin, amoxycillin or
ampicillin, with the option of adding a macrolide
such as intravenous erythromycin, oral azithro-
mycin (also classed as an azalide) or clarithromy-
cin. For the patient in an intensive care unit (ICU),
a second- or third-generation cephalosporin plus
a second-generation quinolone or macrolide is
recommended, with the option of adding rifampi-
cin [6]. North American guidelines for the empir-
ical treatment of CAP patients recommend
inclusion of macrolides to provide coverage
of atypical pathogens, irrespective of the risk
stratiﬁcation of the patient [7,8]. Linezolid is
also effective for hospitalised patients with
CAP [9], and the recent IDSA guidelines for
hospital-acquired, ventilator-associated or health-
care-associated pneumonia recommend linezolid
for patients at high risk of methicillin-resistant
Staphylococcus aureus (MRSA) [10].
In Europe, ceftriaxone is used widely for the
empirical treatment of CAP, with the addition of
an intravenous macrolide such as erythromycin
or clarithromycin. Macrolide and azalide antibi-
otics provide coverage of the main bacterial
pathogens, as well as atypical pathogens, that
are implicated in CAP [11–14]. Studies have
shown that the inclusion of a macrolide with a
second- or third-generation cephalosporin regi-
men can reduce mortality and length of stay in
patients hospitalised with CAP [1,14–16]. The
prototypical macrolide, erythromycin, has a
number of disadvantages that include varying
degress of oral absorption, the need for multiple
daily dosing, high rates of gastrointestinal
adverse events, and sub-optimal antimicrobial
activity against the Gram-negative CAP pathogen
Haemophilus inﬂuenzae and the atypical CAP
pathogen C. pneumoniae [17,18]. The chemical
modiﬁcation of azithromycin gives it pharmaco-
kinetic advantages compared with other macro-
lides, including improved oral bioavailability,
tissue distribution and prolonged elimination
half-life, thereby allowing convenient once-daily
dosing [19]. Moreover, azithromycin provides
coverage for all common CAP pathogens inclu-
ding Strep. pneumoniae, H. inﬂuenzae, Moraxella
catarrhalis [11], C. pneumoniae, M. pneumoniae and
Legionella spp. [20]. Azithromycin has also shown
superior in-vitro activity against H. inﬂuenzae and
Morax. catarrhalis compared with clarithromycin
and erythromycin [21].
Retrospective studies published recently have
reported that macrolide-containing regimens are
associated with improved survival in CAP
patients [22] and decreased lengths of hospital
stay [23]. The aim of the present investigation was
to examine the clinical and bacteriological efﬁcacy
and safety in patients with moderate-to-severe
CAP requiring hospitalisation who received initial
therapy with either intravenous ceftriaxone plus
intravenous azithromycin, followed by step-down
to oral azithromycin, or intravenous ceftriaxone,
combined with either intravenous clarithromycin
or erythromycin, followed by step-down to either
oral clarithromycin or erythromycin.
MATERIALS AND METHODS
Study design
This multicentre study was a prospective, randomised and
open-label clinical trial conducted between April 2002 and
March 2003 in Austria, Belgium, Finland, France, Germany,
Israel, Italy, The Netherlands, Portugal, South Africa, Spain,
Switzerland and Turkey. Patients with CAP requiring hospi-
talisation were assigned randomly to either: (i) intravenous
ceftriaxone 1–2 g once-daily plus intravenous azithromycin
500 mg once-daily for 2–5 days, followed by step-down to oral
azithromycin 500 mg once-daily for a total therapy duration of
7–10 days; or (ii) intravenous ceftriaxone 1–2 g once-daily plus
either intravenous clarithromycin 500 mg twice-daily or eryth-
romycin 1 g three times a day for 2–5 days, followed by step-
down to either oral clarithromycin 500 mg twice-daily or
erythromycin 1 g three times a day for a total of 7–14 days.
Erythromycin was substituted for clarithromycin in those
countries (France, Germany, Israel and The Netherlands) that
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do not have approval for intravenous clarithromycin for the
treatment of CAP. Subjects were assigned randomly to
treatment groups in a ratio of 1:1.
Patients
Male and female patients, aged ‡18 years, with clinical and
radiological ﬁndings consistent with a community-acquired
bronchopneumonia or lobar pneumonia that required hospi-
talisation and initial intravenous antibiotic therapy, were
eligible for enrolment. Speciﬁc inclusion criteria were the
radiographical appearance of a new pulmonary inﬁltrate and
at least two of the following: cough or increasing severity of
coughing; acute changes in sputum quality; oral body tem-
perature or equivalent >38C or <36.1C, or documented fever
or hypothermia within the past 24 h; auscultatory ﬁndings,
such as rales or evidence of pulmonary consolidation;
dyspnoea, tachypnoea, or hypoxaemia; and leukocytosis,
deﬁned as a white blood cell count >10 000/mm3 or >15%
immature neutrophils/bands. In addition, eligible patients had
a minimum APACHE II score of 8.
Patients who presented with any of the following condi-
tions were excluded: females who were pregnant or lactating,
or of childbearing age and not using adequate contraception;
treatment with any systemic antibiotic for ‡24 h within 72 h of
baseline visit, or treatment for >7 days within the past month
unless there was documented evidence of clinical or bacterio-
logical failure; life expectancy of £48 h; AIDS or suspected
Pneumocystis carinii pneumonia; signiﬁcant neutropenia; radio-
logical evidence of cavitary lung disease, primary lung cancer
or metastatic lung malignancy, aspiration pneumonia, empy-
ema or tuberculosis; cystic ﬁbrosis; progressive neoplastic
disease; a history of epilepsy or seizure; or bronchiectasis,
bronchial obstruction or a history of post-obstructive pneu-
monia. Also excluded were patients who were already hospi-
talised or who had resided in a long-term care facility for
>14 days before the onset of symptoms. Written informed
consent was obtained from all patients, and the study received
approval from the institutional review board at each partici-
pating centre, in compliance with Good Clinical Practice
(GPC), including the International Conference on Harmonisa-
tion (ICH) Guidelines, and the most recent version of the
Declaration of Helsinki.
Study visits and procedures
The initial baseline visit (day 1) occurred £24 h before the ﬁrst
dose of study medication, and included eligibility screening,
taking of a medical history, a physical examination, assessment
of APACHE II and Fine Pneumonia Severity Index (PSI) scores,
and pregnancy testing. Assessments for previous antibiotic use,
concomitant medication, healthcare utilisation, vital signs and
clinical signs and symptoms were performed on day 1, daily
during hospitalisation, at the end of therapy (EOT; day 12–16)
and at the end of study (EOS; day 28–35). Sputum samples for
Gram’s stain (an adequate sputum sample was deﬁned as one
containing > 25 polymorphonuclear leukocytes and <10 squa-
mous epithelial cells/low power ﬁeld of a stained specimen),
culture and susceptibility testing, and blood samples for
haematology and biochemistry tests, were obtained on days 1
and 3, at EOT and EOS. Blood samples for culture were taken at
baseline and at other intervals when a previous positive blood
culture had been observed. Chest X-rays were performed on
day 1 and again at EOS; urine samples were obtained on day 1
for detection of Strep. pneumoniae and Legionella urinary
antigens; serum samples were obtained on day 1 and at EOS
for detection of M. pneumoniae, Legionella spp., C. pneumoniae
and Chlamydophila psittaci; and pharyngeal swabs were
obtained on day 1 and at EOS for detection of C. pneumoniae,
M. pneumoniae and Legionella spp. by PCR [24–27]. Assessment
for oral step-down was made on day 3, with patients being
switched to oral therapy if the following criteria were satisﬁed:
oral temperature or equivalent <37.8C for >8 h; cough and
shortness of breath improvement; adequate oral intake and
gastrointestinal absorption; and white blood cell count normal-
ising. Finally, assessment for adverse events took place daily
during hospitalisation and at EOT and EOS.
Detection of atypical pathogens
Serological testing for atypical pathogens was performed by
MDS Pharma Services (Paris, France). Positive IgG serology
was deﬁned as a single titre ‡1:256 for M. pneumoniae, ‡1:512
for C. pneumoniae, ‡1:128 for Legionella pneumophila and ‡1:128
for C. psittaci. PCR testing for atypical pathogens was under-
taken at baseline (day 1). Pharyngeal swab specimens were
tested using PCR for C. pneumoniae, M. pneumoniae and
Legionella spp. by F. Blasi (University of Milan, Milan, Italy)
[24–27]. Touchdown nested PCR was performed using primers
designed to detect the major outer-membrane protein of C.
pneumoniae [24,25], which allows the detection of c. 1–5 C.
pneumoniae elementary bodies. PCR was performed using the
MP8 sense primer and the MP6 antisense primer, selected
from a variable region of the M. pneumoniae 16S rRNA genome
[26]. This PCR technique had a lower detection limit of ten M.
pneumoniae genome equivalents.
Evaluations
Clinical evaluation of response was based on the investigator’s
global assessment of radiological ﬁndings and the clinical
signs and symptoms, including dyspnoea, cough, sputum
volume and character, and fever. Clinical response was
classiﬁed following baseline comparison as cure or failure at
EOS, or as cure, improvement or failure at EOT, according to
the following deﬁnitions: ‘cure’, resolution of signs and
symptoms of pneumonia; ‘improvement’, resolution of fever,
but incomplete resolution of other signs and symptoms of
pneumonia and no requirement for additional antibiotic
treatment; ‘failure’, lack of resolution or deterioration of any
signs and symptoms of pneumonia, and a need for additional
antibiotic treatment. Bacteriological response was classiﬁed as
eradication or persistence of the original causative organism(s)
at EOT and EOS. All treated patients with a medical history
and clinical and radiological ﬁndings consistent with CAP
were included in the clinical modiﬁed intent-to-treat (MITT)
population. A clinically evaluable subgroup excluded MITT
patients who had received <3 days of study medication, or
>120% of the prescribed study medication, or concomitant
systemic antibiotic treatment for intercurrent illness, or who
had missed an evaluation. Analysis of bacteriological response
included those patients in the clinical MITT population who
had at least one causative pathogen isolated at baseline
(bacteriological MITT population), as well as a separate
evaluable population comprising the bacteriological MITT
population who were also considered clinically evaluable.
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The primary efﬁcacy endpoint was clinical response at EOS
for the clinically evaluable patient population. Secondary
endpoints were: clinical response at EOT for clinically evalu-
able patients; clinical response at EOT and EOS for MITT
patients; and bacteriological response at EOT and EOS for
bacteriological MITT and bacteriological evaluable patients.
The length of hospital stay (LOS), total duration of therapy,
and safety and tolerability of the two treatment regimens, were
also assessed. All randomised subjects who received at least
one dose of study medication were included for analysis of
safety and tolerability.
Statistical analysis
In order to establish equivalency between ceftriaxone plus
azithromycin, and ceftriaxone plus clarithromycin/erythro-
mycin, for the treatment of CAP in moderate-to-severely-ill
hospitalised patients, a two-sided 95% CI for the difference in
the rate of clinical and bacteriological response to the two
regimens was calculated. The reference for the comparator
group was estimated to be 90%, the a-level (or value) was 0.05
and the power (b or b-value) was 0.2. Ceftriaxone plus
azithromycin was deemed to be non-inferior to the comparator
regimen if the lower limit of this calculation was ‡ 10%.
RESULTS
Demographics
The baseline demographical characteristics of the
278 hospitalised patients who received treatment
for CAP were comparable for patients in the two
treatment groups (Table 1). Of 143 patients who
were administered ceftriaxone plus clarithromy-
cin/erythromycin, 109 received clarithromycin
and 34 received erythromycin.
Thirty-eight patients in the ceftriaxone plus
azithromycin group, and 47 patients in the
ceftriaxone plus clarithromycin/erythromycin
group, were infected with an atypical pathogen
(C. pneumoniae, M. pneumoniae or Legionella spp.),
or an atypical pathogen plus a conventional
bacterial pathogen, identiﬁed by serology or
PCR at baseline or EOS, equivalent to 32.1% of
the 265 patients from whom serum samples and
pharyngeal swabs were available. In total, 61
(23.0%) patients were infected with an atypical
pathogen alone, and 24 (9.1%) patients were
infected with an atypical pathogen plus a con-
ventional bacterial pathogen. M. pneumoniae was
the atypical pathogen identiﬁed most commonly
(16.2%), followed by C. pneumoniae (10.9%) and
Legionella spp. (6.0%).
Clinical response
In the clinically evaluable population, the clinical
response to ceftriaxone plus azithromycin, and
ceftriaxone plus clarithromycin/erythromycin,
was similar at both EOS and EOT (Fig. 1). The
more stringent MITT analysis, in which missing
values were counted as failures, showed that
success rates were similar to those observed in the
clinically evaluable population. Clinical success
rates at EOT were 84.3% for ceftriaxone plus
azithromycin, and 82.7% for ceftriaxone plus
clarithromycin/erythromycin. Success rates at
EOS (cure only) were 81.7% for ceftriaxone plus
azithromycin, and 75.0% for ceftriaxone plus
clarithromycin/erythromycin. When Fine PSI cat-
egories and APACHE II scores were used to
classify patients according to disease severity,
there were no major differences in clinical success
rates between patients in either treatment group
(Table 2).
Table 1. Patient demographics
CEF/AZM CEF/C or E
Total no. 135 143
Male, n (%) 94 (70) 97 (68)
Female, n (%) 41 (30) 46 (32)
Age
Mean, years (SD) 64.2 ± 17.1 62.4 ± 18.7
>65 years, n (%) 85 (63) 82 (57)
Smoking history
Smoker 30 (22) 54 (38)a
Ex-smoker 62 (46) 47 (33)
Never smoked 42 (31) 42 (29)
Mean APACHE score ± SD 13.3 ± 4.3 12.6 ± 4.1
Mean Fine PSI ± SD 91.8 ± 27.2 92.2 ± 26.0
Fine PSI category, n (%)
I or II (<71) 27 (20) 33 (23.1)
III (71–90) 37 (27.4) 37 (25.9)
IV (91–130) 62 (45.9) 65 (45.5)
V (>131) 9 (6.7) 8 (5.6)
CEF, ceftriaxone; AZM, azithromycin; C, clarithromycin; E, erythromycin; SD,
standard deviation; PSI, pneumonia severity index.
ap 0.05.
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Fig. 1. Clinical success at end of therapy (EOT; cure or
improvement) and end of study (EOS; cure only) in the
clinically evaluable population (one subject infected with
an atypical pathogen and a conventional bacterial patho-
gen was randomised to receive azithromycin but actually
received erythromycin).
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Symptom resolution was also similar for
patients treated with ceftriaxone plus azithromy-
cin, or ceftriaxone plus clarithromycin/erythro-
mycin. Based on signs and symptoms at baseline
that affected > 80% of the clinical MITT popula-
tion, cough, dyspnoea, rales and sputum produc-
tion were still observed at EOS in 23.7%, 22.9%,
16.2% and 19.0%, respectively, of the ceftriaxone
plus azithromycin group, compared with 30.0%,
19.5%, 22.3% and 16.8% of the ceftriaxone plus
clarithromycin/erythromycin group.
Bacteriological response
In total, 87 (31.3%) patients in the two treatment
groups had a pathogen associatedwith respiratory
illness isolated at baseline, and were included in
the bacteriological MITT population. The patho-
gens isolated most frequently at baseline were
Strep. pneumoniae,H. inﬂuenzae and Staph. aureus. Of
those patients in the bacteriological MITT popula-
tion who received treatment with ceftriaxone plus
azithromycin, or ceftriaxone plus clarithromycin/
erythromycin, Strep. pneumoniaewas isolated from
44% and 57% of patients, respectively, H. inﬂuen-
zae from 25% and 18%, respectively, and Staph.
aureus from 13% and 4%, respectively. Other
organisms identiﬁed at baseline included Haemo-
philus parainﬂuenzae (6%, 9%), Pseudomonas aerugi-
nosa (6%, 4%) and Morax. catarrhalis (2%, 2%).
Thirteen patients in the azithromycin plus ceftri-
axone group, and ten patients in the ceftriaxone
plus clarithromycin/erythromycin group, had
more than one pathogen isolated at baseline.
Table 3 summarises bacteriological eradication
in both the bacteriological MITT and evaluable
populations, and clinical success according to
baseline pathogen in the bacteriological MITT
population. Bacteriological eradication rates at
EOT and EOS were similar for the two treatment
groups in the bacteriological evaluable popula-
tion. However, in the bacteriological MITT pop-
ulation, bacteriological eradication rates were
superior (not signiﬁcant) at both EOT and EOS
for the ceftriaxone plus azithromycin group
(73.2% and 68.3%, respectively) compared with
the ceftriaxone plus clarithromycin/erythromycin
group (67.4% and 60.9%, respectively). When
clinical success was determined according to
baseline pathogen, treatment with ceftriaxone
plus azithromycin, or ceftriaxone plus clarithro-
mycin/erythromycin, demonstrated equivalent
clinical success rates in patients with Strep. pneu-
Table 2. Clinical responses at end of therapy (EOT)
according to disease severity classiﬁed by APACHE score
and Fine PSI category
Clinical MITT response at EOT
95% CI CEF/AZM CEF/C or E
APACHE II score
5–9 87.5% (21/24) 87.9% (29/33) –
10–14 84.7% (50/59) 78.6% (44/56) –
15–19 85.2% (23/27) 86.2% (25/29) –
20–24 85.7% (6/7) 75.0% (6/8) –
25–30 50.0% (2/4) – –
Fine PSI category
III 77.1 (27/35) 80% (28/35) ) 22.1%, 16.4%
IV 86.8% (46/53) 82.1% (46/52) ) 8.9%, 18.2%
V 77.8% (7/9) 85.7% (6/7) ) 45.5%, 29.6%
AZM, azithromycin; CEF, ceftriaxone; C, clarithromycin; E, erythromycin; MITT,
modiﬁed intent-to-treat; PSI, pneumonia severity index.
Table 3. Clinical success deter-
mined according to bacteriological
eradication in the bacteriological
modiﬁed intent-to-treat (MITT) and
evaluable populations, or according
to baseline pathogen in the bacterio-
logical MITT population and in
patients with atypical pathogens
Outcome
EOT (day 12–16) EOS (day 28–35)
CEF/AZM
% (n)
CEF/C or E
% (n)
CEF/AZM
% (n)
CEF/C or E
% (n)
Bacteriological eradication
MITT population 73.2 (30/41) 67.4 (31/46) 68.3 (28/41) 60.9 (28/46)
Evaluable 80.0 (24/31) 80.6 (25/31) 72.7 (16/22) 74.2 (23/31)
Clinical success by baseline pathogena
in bacteriological MITT population
Streptococcus pneumoniae 81.0 (17/21) 70.0 (21/30) 75.0 (15/20) 66.7 (20/30)
Haemophilus inﬂuenzae 92.3 (12/13) 50.0 (4/8) 92.3 (12/13) 37.5 (3/8)
Staphylococcus aureus 83.3 (5/6) 100 (1/1) 83.3 (5/6) 100 (1/1)
Clinical success in patients with atypical
pathogens in clinical MITT population
Mycoplasma pneumoniae 88.9 (8/9) 77.8 (7/9) 88.9 (8/9) 77.8 (7/9)
Chlamydia pneumoniae 100.0 (6/6) 77.8 (7/9) 100.0 (8/8) 66.7 (6/9)
Legionella spp. 50.0 (1/2) 71.4 (5/7) 0 (0/1) 75.0 (6/8)
Clinical success in patients with positive
blood cultures
MITT 66.7 (8/12) 58.8 (10/17)b 66.7 (8/12) 52.9 (9/17)b
CEF, ceftriaxone; AZM, azithromycin; C, clarithromycin; E, erythromycin; EOT, end of therapy; EOS, end of study.
aNineteen patients had two or more pathogens at baseline (six and four patients were cured in the CEF/AZM and
CEF/C or E groups, respectively).
bNot signiﬁcantly different compared with CEF/AZM.
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moniae or Staph. aureus as a baseline pathogen.
Although the number of evaluable patients was
relatively small, there was a trend towards
improved clinical success in patients with
H. inﬂuenzae as a baseline pathogen who were
treated with ceftriaxone plus azithromycin. At
EOS, clinical success in response to H. inﬂuenzae
was observed in 12 (92.3%) of 13 patients treated
with ceftriaxone plus azithromycin, compared
with three (37.5%) of eight patients treated with
ceftriaxone plus clarithromycin/erythromycin.
Clinical success was observed at both EOT and
EOS for one patient from each treatment group
with Morax. catarrhalis isolated at baseline (data
not shown). In the population of patients with
severe illness (Fine PSI categories IV and V) and
positive baseline cultures, 42 patients were eval-
uable; clinical cure was observed in 20 (90.9%) of
22 patients treated with ceftriaxone plus azithro-
mycin, compared with 14 (70.0%) of 20 patients
who received ceftriaxone plus clarithromycin/
erythromycin.
There was a small number of patients in the
bacteriological MITT population from whom
Strep. pneumoniae was isolated from the baseline
blood cultures. Bacteriological success rates were
similar in both treatment groups at EOT and EOS
(Table 4).
In patients with an atypical pathogen only,
clinical success (cure) at EOS was observed in a
higher proportion (not signiﬁcant) of patients
treated with ceftriaxone plus azithromycin (18 of
20; 90%) compared with patients who received
ceftriaxone plus clarithromycin/erythromycin (24
of 30; 80%). In patients with both an atypical
pathogen and a conventional bacterial pathogen,
nine (90%) of ten patients treated with ceftriaxone
plus azithromycin showed a clinical cure, com-
pared with six (54.5%) of 11 patients treated with
ceftriaxone plus clarithromycin/erythromycin.
Clinical success at EOT was higher with ceftriax-
one plus azithromycin, with 17 (89.5%) of 19
patients with an atypical pathogen, and ten
(90.9%) of 11 patients with both an atypical and
a conventional bacterial pathogen, showing
clinical cure, compared with 24 (80.0%) of 30
and seven (63.6%) of 11 patients treated with
ceftriaxone plus clarithromycin/erythromycin.
Healthcare resource utilisation
Analysis of healthcare utilisation data indicated
an advantage (not signiﬁcant) for treatment with
ceftriaxone plus azithromycin, compared with
ceftriaxone plus clarithromycin/erythromycin,
for hospitalised patients with CAP. In the group
treated with ceftriaxone plus azithromycin, the
mean (± SD) hospital LOS was 10.7 (6.8) days,
compared with 12.6 (10.8) days for patients
treated with ceftriaxone plus clarithromycin/
erythromycin. There was also an advantage (not
signiﬁcant) in treatment with ceftriaxone plus
azithromycin in terms of mean duration of ther-
apy, with a total duration of intravenous and oral
therapy of 9.5 days, compared with 10.5 days for
patients treated with ceftriaxone plus clarithro-
mycin/erythromycin. The mean time from intra-
venous initiation to oral switch was 5.0 days for
patients treated with ceftriaxone plus azithromy-
cin, and 4.7 days for patients treated with ceftri-
axone plus clarithromycin/erythromycin.
Patients with an atypical pathogen, or an
atypical pathogen and a conventional bacterial
pathogen, had a reduction in mean hospital LOS
of 3.6 days and 3.3 days, respectively, when
treated with ceftriaxone plus azithromycin, com-
pared with ceftriaxone plus clarithromycin/
erythromycin (Fig. 2). Patients with an atypical
pathogen, or an atypical pathogen and a conven-
tional bacterial pathogen, also had a shorter mean
duration of intravenous and oral therapy when
treated with ceftriaxone plus azithromycin,
compared with ceftriaxone plus clarithromycin/
erythromycin (atypical pathogen, 9.2 vs.
10.3 days, respectively; atypical plus conventional
Table 4. Bacteriological response in patients with Strepto-
coccus pneumoniae isolated from baseline blood culture
(bacteriological modiﬁed intent-to-treat population; n (%)
of patients)
Visit Bacteriological response CEF/AZM CEF/C or E
Subjects evaluable
at the EOT visit
12 (100) 17 (100)
EOT (Visit 3) Success 8 (66.7) 12 (70.6)
Eradication 3 3
Presumed eradication 5 9
Failure 4 (33.3) 5 (29.4)
Presumed persistence 2 5
Persistence 0 0
Unknown 2 0
Subjects evaluable
at the EOS visit
12 (100.0) 17 (100.0)
EOS (Visit 4) Success 7 (58.3) 9 (52.9)
Eradication 4 2
Presumed eradication 3 7
Failure 5 (41.7) 8 (47.1)
Presumed persistence 3 8
Unknown 2 0
CEF, ceftriaxone; AZM, azithromycin; C, clarithromycin; E, erythromycin; EOT, end
of therapy; EOS, end of study.
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bacterial pathogen, 9.3 vs. 10.1 days, respect-
ively). This reduction was attributable largely to
a reduction in the mean duration of oral dosing of
0.8 days (atypical pathogen) and 1.2 days (atyp-
ical plus conventional bacterial pathogen) when
patients were treated with ceftriaxone plus azith-
romycin, compared with ceftriaxone plus clarith-
romycin/erythromycin.
Safety and tolerability
Overall, a slightly lower proportion of patients
treated with ceftriaxone plus azithromycin report-
ed a treatment-related adverse event (44/135,
32.6%) compared with those treated with ceftriax-
one plus clarithromycin/erythromycin (58/143,
40.6%). All adverse events in the ceftriaxone plus
azithromycin group were classiﬁed as mild or
moderate in severity. Three adverse events in the
ceftriaxone plus clarithromycin/erythromycin
group were classiﬁed as severe, comprising injec-
tion site inﬂammation (the subject discontinued
participation in the study), injection site pain
(intravenous erythromycin was discontinued and
the patientwas switched to oral erythromycin) and
hepatic enzyme increase (no action was taken).
As shown in Table 5, signiﬁcantly more
patients in the ceftriaxone plus clarithromycin/
erythromycin group reported infusion-related
adverse events compared with patients treated
with ceftriaxone plus azithromycin (23.8% vs.
14.1%, p 0.04). Among patients treated with
ceftriaxone plus clarithromycin/erythromycin,
24 (22.0%) of 109 patients in the clarithromycin
arm, and ten (29.4%) of 34 patients in the
erythromycin arm, reported infusion-related ad-
verse events. Most infusion-related adverse
events were mild in severity, but two (5.9%) of
34 patients treated with ceftriaxone plus clarith-
romycin/erythromycin reported severe infusion-
related adverse events, compared with none in
the ceftriaxone plus azithromycin group. Infu-
sion-related adverse events persisted for a similar
mean length of time in the two groups: 4.4 (3.9)
days in the ceftriaxone plus azithromycin group,
compared with 4.7 (5.6) days in the ceftriaxone
plus clarithromycin/erythromycin group.
Gastrointestinal adverse events were reported
by 17 (12.6%) of 135 patients treated with ceftri-
axone plus azithromycin, compared with 26
(18.2%) of 143 patients treated with ceftriaxone
plus clarithromycin/erythromycin. As shown in
Table 5, diarrhoea was the intestinal adverse
event reported most frequently, affecting similar
proportions of patients in each treatment group.
One patient in the ceftriaxone plus azithromycin
group discontinued treatment because of elevated
hepatic enzyme levels, while four patients in
the ceftriaxone plus clarithromycin/erythro-
mycin group discontinued treatment because of:
(i) cutaneous erythematous eruption; (ii) anorexia,
emesis, urticaria and taste perversion; (iii) emesis
and hearing loss on left side; and (iv) phlebitis of
left hand at the infusion site. Finally, there were
seven deaths in the ceftriaxone plus azithromycin
group, and ﬁve deaths in the ceftriaxone plus
clarithromycin/erythromycin group, either dur-
ing the study or within 35 days of the ﬁnal dose of
treatment. None of these deaths was considered
to be treatment related.
DISCUSSION
This study demonstrates that treatment of
patients who require hospitalisation because of
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Fig. 2. Mean length of hospital stay for patients in the two
treatment groups with an atypical pathogen, or an atypical
and a conventional bacterial pathogen, identiﬁed during
the course of the study.
Table 5. Treatment-related adverse events affecting
patients in the two treatment groups
CEF/AZM
(total n = 135)
n (%)
CEF/C or E
(total n = 143)
n (%)
Infusion-related events
Application site infection/inﬂammation 14 (14.1) 34 (23.8)
Application site pain 2 (1.5) 9 (6.3)
Gastrointestinal events 17 (12.6) 26 (18.2)
Diarrhoea 10 (7.4) 12 (8.4)
Nausea 2 (1.5) 7 (4.9)
Hepatic enzymes increased 4 (3.0) 4 (2.8)
CEF, ceftriaxone; AZM, azithromycin; C, clarithromycin; E, erythromycin.
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moderate-to-severe CAP with initial intravenous
ceftriaxone plus azithromycin, followed by oral
azithromycin, is equal in efﬁcacy and safety to a
standard regimen of intravenous ceftriaxone plus
either clarithromycin or erythromycin, followed
by step-down to oral clarithromycin or erythro-
mycin. Using the more stringent criteria of MITT,
where subjects with missing clinical outcome data
were classiﬁed as therapeutic failures, the clinical
cure rate was at least as good as that obtained
with the comparator therapy at EOS. In addition,
ceftriaxone plus azithromycin therapy achieved
equivalent clinical success at EOT, independent of
the APACHE II score or PSI category. However,
the lower number of subjects in the Fine PSI
category III and V groups meant that these data
are associated with larger CIs.
Bacterial eradication and clinical success by
baseline pathogen were equivalent for the two
antimicrobial regimens, although there was a
non-signiﬁcant effect favouring ceftriaxone plus
azithromycin for patients with H. inﬂuenzae isola-
ted at baseline. Atypical coverage also favoured
ceftriaxone plus azithromycin, with higher clin-
ical success rates (not signiﬁcant) at both EOT and
EOS, compared with ceftriaxone plus clarithro-
mycin/erythromycin. In the patients who had a
positive blood culture at baseline, the clinical
response rates did not differ between the two
groups. Furthermore, ceftriaxone plus azithromy-
cin had a comparable overall safety proﬁle, with
fewer infusion-related adverse events (p 0.04).
Causative pathogens cannot be identiﬁed in
50–60% of CAP patients, even when extensive
testing is undertaken [1,28–31]. In the present
study, causative pathogens were identiﬁed in
53% of subjects at baseline (22% of patients were
positive for an atypical respiratory pathogen
alone using serology and PCR testing), which is
consistent with other studies.
Updated clinical guidelines have delineated a
role for azithromycin as oral therapy in outpa-
tients [7,8], as oral therapy in combination with an
intravenous cephalosporin for use in the medical
ward [6], as intravenous therapy for use in the
medical ward, either alone [7] or in combination
with a cephalosporin [8], and in the ICU in
combination with a cephalosporin [7,8]. In com-
parison with a standard therapeutic regimen that
followed American Thoracic Society (ATS) guide-
lines, azithromycin has been shown to be as
effective and at least as safe when administered as
initial intravenous therapy to hospitalised pa-
tients with CAP, either as monotherapy [3,13,32]
or in combination with a cephalosporin [33]. The
combination of a macrolide and a cephalosporin
has been associated with improved patient out-
comes, which include reduced mortality [1,14–16]
and LOS [15]. Adverse events were signiﬁcantly
less common with azithromycin-containing regi-
mens than with regimens containing erythromy-
cin, with the latter being associated with higher
rates of gastrointestinal disturbances and infu-
sion-related events [3,13], which reﬂects the ﬁnd-
ings of the present investigation.
The use of azithromycin together with a cep-
halosporin may have advantages over other
macrolide/cephalosporin combinations, as dos-
ing is once-daily. Combined with a lower rate of
gastrointestinal disturbance, this may improve
compliance in patients switched to oral therapy
[6,19]. Notable microbiological features of azith-
romycin are superior in-vitro activity against
H. inﬂuenzae compared with both erythromycin
and clarithromycin [11,21,34], and superior
activity compared with erythromycin against
C. pneumoniae [16]. While the cost of azithromycin
may exceed other macrolides, overall costs may
be offset by decreased duration of therapy, lower
preparation and administration costs, and
reduced LOS [3,35].
Although the present study was designed to
demonstrate equivalency rather than differences
between ceftriaxone plus azithromycin and the
comparator regimen, non-signiﬁcant trends did
emerge in terms of reduced duration of therapy
and LOS that favoured ceftriaxone plus azithro-
mycin. This was particularly evident for the 32%
of patients from whom an atypical pathogen, or
an atypical plus a typical pathogen, was isolated
during the course of the study, with LOS being
reduced by >3 days for patients treated with
ceftriaxone plus azithromycin, compared with
ceftriaxone plus clarithromycin/erythromycin.
Furthermore, clinical success rates among pa-
tients with an atypical pathogen were greater in
response to ceftriaxone plus azithromycin. Atyp-
ical pathogens such as C. pneumoniae, M. pneumo-
niae and Legionella spp. are implicated in up to
40% of CAP cases [5], further emphasising the
need to provide adequate coverage during initial
empirical therapy.
In conclusion, an intravenous-to-oral antimi-
crobial regimen of ceftriaxone plus azithro-
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mycin appears to be at least as effective and
well-tolerated as a standard regimen of ceftriax-
one plus clarithromycin or erythromycin, and is a
suitable treatment option for moderate-to-se-
verely-ill patients hospitalised with CAP. Fur-
thermore, ceftriaxone plus azithromycin may be a
better treatment option in terms of reducing the
duration of therapy and LOS, and may be asso-
ciated with improved tolerance in patients
switched to oral therapy. Further research is
needed to conﬁrm these ﬁndings.
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